Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

@article{Mueller2014LowMR,
  title={Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.},
  author={Judith Mueller and Oscar Krijgsman and Jennifer Tsoi and L{\'i}dia Robert and Willy Hugo and Chunying Song and Xiangju Kong and Patricia Abr{\~a}o Possik and Paulien D M Cornelissen-Steijger and Marnix H. Geukes Foppen and Kristel Kemper and C. R. Goding and Ultan McDermott and Christian U Blank and John B A G Haanen and Thomas G Graeber and Antoni Ribas and Roger S. Lo and Daniel S Peeper},
  journal={Nature communications},
  year={2014},
  volume={5},
  pages={5712}
}
Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway inhibition. Here we show that the lack of MITF is associated with more severe resistance to a range of inhibitors, while its presence is required for robust drug responses. Both in primary and acquired resistance, MITF levels inversely correlate with the expression of several activated receptor tyrosine kinases, most frequently AXL. The MITF-low… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS